Structural and Mechanistic Underpinnings of the Differential Drug Sensitivity of EGFR Mutations in Non-small Cell Lung Cancer

Overview

Journal Biochim Biophys Acta

Specialties Biochemistry
Biophysics

Date 2009 Dec 23

PMID 20026433

Citations 91

Authors

Michael J Eck

Cai-Hong Yun

Affiliations

Soon will be listed here.

Abstract

EGFR and other ErbB-family tyrosine kinases are overexpressed in many human tumors, and their aberrant expression and mutational activation is associated with the development, progression and aggressiveness of a number of malignancies. Thus the EGFR kinase has long been recognized as a potential drug target in oncology, and small-molecule inhibitors have been under development for more than two decades. As a result of their effectiveness in treating non-small cell lung cancers (NSCLCs) driven by somatic mutations in the EGFR kinase, gefitinib and erlotinib were the first EGFR tyrosine kinase inhibitors (TKIs) approved for clinical use. Ironically, these drugs found their target against mutant forms of the EGFR kinase, which have altered enzyme active sites, and not against the wild type (WT) kinase against which their potency and selectivity was carefully honed. Here we review recent structural and enzymological studies that explore the exquisite sensitivity of a subset of these lung cancer mutants to gefitinib and erlotinib. We discuss available structural evidence for the mechanisms of activation of the EGFR kinase by these mutants, and compare it to physiologic activation of the kinase by ligand-induced dimerization. Finally, we consider the mechanisms by which the secondary T790M "gatekeeper" mutation confers resistance to gefitinib and erlotinib.

Citing Articles

Lazertinib: breaking the mold of third-generation EGFR inhibitors.

Patel K, Heppner D RSC Med Chem. 2025; .

PMID: 39867588 PMC: 11758113. DOI: 10.1039/d4md00800f.

Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer.

Milgram B, Borrelli D, Brooijmans N, Henderson J, Hilbert B, Huff M J Med Chem. 2025; 68(3):2403-2421.

PMID: 39824516 PMC: 11831596. DOI: 10.1021/acs.jmedchem.4c02377.

combined with L858R mutation reduced afatinib sensitivity and associated to early recurrence in lung cancer.

Terada N, Koba H, Nanjo S, Kimura H, Nishiyama A, Yoneda T Transl Lung Cancer Res. 2024; 13(11):3067-3082.

PMID: 39670006 PMC: 11632430. DOI: 10.21037/tlcr-24-471.

Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity.

Zhao H, Beyett T, Jiang J, Rana J, Schaeffner I, Santana J Proc Natl Acad Sci U S A. 2024; 121(45):e2417144121.

PMID: 39471218 PMC: 11551396. DOI: 10.1073/pnas.2417144121.

[EGFR Exon 20 Insertion Mutation: Research Status and New Treatment Strategies].

Tian M, Wang N, Dou Z, Song X, Zhang X Zhongguo Fei Ai Za Zhi. 2024; 27(8):579-592.

PMID: 39318251 PMC: 11425684. DOI: 10.3779/j.issn.1009-3419.2024.106.19.

References

Carey K, Garton A, Romero M, Kahler J, Thomson S, Ross S . Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 2006; 66(16):8163-71. DOI: 10.1158/0008-5472.CAN-06-0453. View

Lemmon M . Ligand-induced ErbB receptor dimerization. Exp Cell Res. 2008; 315(4):638-48. PMC: 2667204. DOI: 10.1016/j.yexcr.2008.10.024. View

Greulich H, Chen T, Feng W, Janne P, Alvarez J, Zappaterra M . Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005; 2(11):e313. PMC: 1240052. DOI: 10.1371/journal.pmed.0020313. View

Chan S, Gullick W, Hill M . Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy. Eur J Cancer. 2005; 42(1):17-23. DOI: 10.1016/j.ejca.2005.07.031. View

Kobayashi S, Boggon T, Dayaram T, Janne P, Kocher O, Meyerson M . EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352(8):786-92. DOI: 10.1056/NEJMoa044238. View

Roche-Lestienne C, Soenen-Cornu V, Lai J, Philippe N, Facon T, Fenaux P . Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002; 100(3):1014-8. DOI: 10.1182/blood.v100.3.1014. View

Sharma S, Gajowniczek P, Way I, Lee D, Jiang J, Yuza Y . A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell. 2006; 10(5):425-35. PMC: 2673136. DOI: 10.1016/j.ccr.2006.09.014. View

Stamos J, Sliwkowski M, Eigenbrot C . Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem. 2002; 277(48):46265-72. DOI: 10.1074/jbc.M207135200. View

Kumar A, Petri E, Halmos B, Boggon T . Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol. 2008; 26(10):1742-51. PMC: 3799959. DOI: 10.1200/JCO.2007.12.1178. View

10.

Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A . A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology. 2004; 127(1):294-9. DOI: 10.1053/j.gastro.2004.02.021. View

11.

Yun C, Mengwasser K, Toms A, Woo M, Greulich H, Wong K . The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105(6):2070-5. PMC: 2538882. DOI: 10.1073/pnas.0709662105. View

12.

Cools J, DeAngelo D, Gotlib J, Stover E, Legare R, Cortes J . A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348(13):1201-14. DOI: 10.1056/NEJMoa025217. View

13.

Qiu C, Tarrant M, Boronina T, Longo P, Kavran J, Cole R . In vitro enzymatic characterization of near full length EGFR in activated and inhibited states. Biochemistry. 2009; 48(28):6624-32. PMC: 2747374. DOI: 10.1021/bi900755n. View

14.

Jura N, Endres N, Engel K, Deindl S, Das R, Lamers M . Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell. 2009; 137(7):1293-307. PMC: 2814540. DOI: 10.1016/j.cell.2009.04.025. View

15.

Brewer M, Choi S, Alvarado D, Moravcevic K, Pozzi A, Lemmon M . The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell. 2009; 34(6):641-51. PMC: 2719887. DOI: 10.1016/j.molcel.2009.04.034. View

16.

Shah N, Nicoll J, Nagar B, Gorre M, Paquette R, Kuriyan J . Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002; 2(2):117-25. DOI: 10.1016/s1535-6108(02)00096-x. View

17.

Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M . Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res. 2006; 12(19):5764-9. DOI: 10.1158/1078-0432.CCR-06-0714. View

18.

Wood E, Truesdale A, McDonald O, Yuan D, Hassell A, Dickerson S . A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004; 64(18):6652-9. DOI: 10.1158/0008-5472.CAN-04-1168. View

19.

Zhang X, Gureasko J, Shen K, Cole P, Kuriyan J . An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell. 2006; 125(6):1137-49. DOI: 10.1016/j.cell.2006.05.013. View

20.

Gazdar A, Shigematsu H, Herz J, Minna J . Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?. Trends Mol Med. 2004; 10(10):481-6. DOI: 10.1016/j.molmed.2004.08.008. View